Bioconversion of AS1387392: Screening and characterization of actinomycetes that convert AS1387392 to AS1429716

Journal of Antibiotics

Volumn 63, Issue 11, 2010, Pages 637-642

  Sasamura, Satoshi ^a   Muramatsu, Hideyuki ^b   Takase, Shigehiro ^c   Fujie, Akihiko ^d   Fujii, Takashi ^e,g   Hino, Motohiro ^f   Sakamoto, Kazutoshi ^b   Hashimoto, Michizane ^b  

^a Astellas Pharma   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

^c Analysis and Pharmacokinetics Research Laboratories   (Japan)

^d Astellas Pharma   (Japan)

^e Exploratory Research Laboratories   (Japan)

^f Astellas Pharma   (Japan)

^g Kikuchi Research Center   (Japan)

Author keywords

Acremonium; AS1387392; AS1429716; bioconversion; histone deacetylase inhibitor; immunosuppressant

Indexed keywords

AS 1387392; AS 1429716; DNA 16S; ENZYME INHIBITOR; UNCLASSIFIED DRUG;

ACTINOBACTERIA; AMYCOLATOPSIS; ARTICLE; BACTERIAL STRAIN; DNA SEQUENCE; DRUG ABSORPTION; DRUG ISOLATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSFORMATION; HYDROXYLATION; LENTZEA; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SACCHAROPOLYSPORA; SPHAERISPORANGIUM;

ACTINOBACTERIA; BASE SEQUENCE; DNA, BACTERIAL; DNA, RIBOSOMAL; HISTONE DEACETYLASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; PEPTIDES, CYCLIC; PHYLOGENY; SPECIES SPECIFICITY;

ACTINOBACTERIA (CLASS); AMYCOLATOPSIS; LENTZEA; SACCHAROPOLYSPORA;

EID: 78649654106     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.1038/ja.2010.89     Document Type: Article

References (26)

1. Su, Q. L., Weber, M., Hir, M. L., Zenke, G. & Ryffel, B. Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase. Ren. Physiol. Biochem. 18, 128-139 (1995).
2. Bechstein, W. O. Neurotoxicity of calcineurin inhibitors: impact and clinical manage-ment. Transpl. Int. 13, 313-326 (2000).
3. Sasamura, S. et al. AS1387392, a novel immunosuppressive cyclic tetrapeptide compound with inhibitory activityagainst mammalian histone deacetylase. J. Antibiot. 63: (in submitted) (2010).
4. Mori, H. et al. FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian histone deacetylase (HDAC). I. Taxonomy, fermentation, isolation and biological activities. J. Antibiot. 56, 72-79 (2003). (Pubitemid 36372787)
5. Mori, H. et al. FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian histone deacetylase (HDAC). III. Structure determination. J. Antibiot. 56, 181-185 (2003). (Pubitemid 36372803)
6. Mori, H. et al. FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian histone deacetylase (HDAC). II. Biological activities in animal models. J. Antibiot. 56, 80-86 (2003). (Pubitemid 36372788)
7. Serizawa, N., Serizawa, S., Furuya, K., Okazaki, T. & Terahara, A. Microbial hydroxyla-tion of ML-236B (compactin). Studies on microorganisms capable of 3 beta-hydro-xylation of ML-236B. J. Antibiot. 36, 887-891 (1983).
8. Sasaki, J. et al. Transformation of vitamin D3 to 1α, 25-dihydroxyvitamine D3 via 25-hydroxyvitamine D3 using Amycolatasp. strains. Appl. Microbiol. Biotechnol. 38, 152-157 (1992).
9. Schulman, M., Doherty, P.,Zink, D.&Arison, B. Microbial conversion of avermectins by Saccharopolyspora erthraea hydroxylation at C-27. J. Antibiot. 47, 372-375 (1994).
10. Nakagawa, K. & Torikata, A. Microbial conversion of milbemycins: 30-oxidation of milbemycin A4 and relatedcompounds byAmycolatataautotrophicaand amycolatopsis mediterranei. J. Antibiot. 43, 1321-1328 (1990).
11. Hall, R. M. et al. The production of novel sordarin analogues by transformation. J. Antibiot. 54, 948-957 (2001).
12. Nakagawa, Y. & Kawasaki, H. Identification Manual of Actinomycetes. Edited by The Society forActinomycetes Japan 83-117 (Business Center for Academic Societies Japan, Tokyo, 2001) (in Japanese).
13. Thompson, J. D., Higgins, D. G. & Gibson, T. J. CLUSTALW improvingthesensitivity of progressive multiplesequencealignmentthrough sequenceweighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22, 4673-4680 (1994).
14. Shirling, E. B. & Gottlieb, D. Methods for characterization of Streptomyces species. Int. J. Syst. Bacteriol. 16, 313-340 (1966).
15. Waksman, S. A. The Actinomycetes Vol. 2: Classification, identification and description ofgenera andspecies(Williamsand Wilkins, Baltimore, 1961).
16. Pridham, T. G. & Gottlieb, D. The utilization of carbon compounds by some Actinomy-cet ales as an acid for species determination. J. Bacteriol. 56, 107-114 (1948).
17. Kornerup, A. &Wanscher, J. H Methuen HandbookofColour(Methuen, London, 1978).
18. Becker, B., Lechevalier, M. P., Gordon, R. E. & Lechevalier, H. A. Rapid differentiation between Nocardia and Streptomyces by paper chromatography of whole-cell hydro-lysates. Appl. Microbiol. 12, 421-423 (1964).
19. Lechevalier, M. P. & Lechevalier, H. A. Chemical composition as a criterion in the classification of aerobic actinomycetes. Int. J. Syst. Bacteriol. 20, 435-443 (1970).
20. Williams, S. T. Bergey's Manual ofSystematic Bacteriology, Vol. 4. (Williams and Wilkins, Baltimore, 1989).
21. Tanaka, M. et al. Microbial hydroxylation of Zofimarin, a sordarin-related antibiotic. J. Antibiot. 55, 437-441 (2002).
22. sca from Streptomycescarbophilus. Eur. J. Biochem. 184, 707-713 (1989).
23. Berrie, J. R., Williams, A. D. R. & Smith, K. E. Microbial transformations of steroid-XI. Progesterone transformation by Streptomyces roseochromogenens-purification and characterization of the 16α-hydroxylase system. J. Steroid Biochem. Mol. Biol. 71, 153-165 (1999).
24. Muramatsu, H., Shahab, N., Tsurumi, Y. & Hino, M. A comparative study of malaysian and Japanease Actinomycetes using a simple identification method based on partial 16S rDNA sequence. Actinomycetologica 17, 33-43 (2003).
25. Stackebrandt, E. & Goebel, B. M. Taxonomic note: a place for DNA-DNA reassociation and 16S rRNA sequence analysis in the present species definition in bacteriology. Int. J. Syst. Bacteriol. 44, 846-849 (1994).
26. Satoh, S. et al. Cyclictetrapeptidecompound and usethereof. WO 03/057722 July 17 (2003).